Development

Retatrutide reports phase-three weight-loss results

development2026-09-30biotech

Claim

The newsletter reports Lilly's retatrutide reducing body weight by up to 25% in phase three, without supplying the full trial population or protocol.

Reported metric: up to 25%; phase 3

Reporting date: 2026-09-30 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to September 30, 2026 (theinnermostloop.substack.com)
Source linked by the September 30 issue (www.nejm.org)

Indexed from the September 30 newsletter. Linked-source claims have not been independently verified.

Knowledge graphopen in browser →

Reported in

Welcome to September 30, 2026

Actor

Eli Lilly

Referenced by

Welcome to September 30, 2026

Cite or correct this record

Citation formatCitation text

Retatrutide reports phase-three weight-loss results
Innermost Loop KB — secondary record
Reporting date: 2026-09-30
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-09-30-retatrutide-trial
Claim: The newsletter reports Lilly's retatrutide reducing body weight by up to 25% in phase three, without supplying the full trial population or protocol.
Attributed sources:
- Welcome to September 30, 2026 — https://theinnermostloop.substack.com/p/welcome-to-september-30-2026
- Source linked by the September 30 issue — https://www.nejm.org/doi/full/10.1056/NEJMoa2604169
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.